Stockscreener 앱 받기
34.08
2.34%
0.78
시간 외 거래:
35.40
1.32
+3.87%
전일 마감가:
$33.30
열려 있는:
$32.95
하루 거래량:
1.24M
Relative Volume:
0.58
시가총액:
$3.63B
수익:
$761.41M
순이익/손실:
$98.16M
주가수익비율:
41.66
EPS:
0.8181
순현금흐름:
$141.79M
1주 성능:
+5.22%
1개월 성능:
-0.47%
6개월 성능:
-57.68%
1년 성능:
-41.24%
1일 변동 폭
$32.89
$34.25
1주일 범위
$31.81
$34.25
52주 변동 폭
$28.66
$117.33
코르셉트 테라퓨틱스 Stock (CORT) Company Profile
명칭
Corcept Therapeutics Inc
전화
650.688.8803
주소
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Compare CORT vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
34.08 | 3.54B | 761.41M | 98.16M | 141.79M | 0.8181 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
코르셉트 테라퓨틱스 Stock (CORT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-31 | 다운그레이드 | Wolfe Research | Peer Perform → Underperform |
| 2025-12-16 | 개시 | UBS | Neutral |
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2023-11-06 | 업그레이드 | Truist | Hold → Buy |
| 2023-04-11 | 개시 | SVB Securities | Market Perform |
| 2023-04-04 | 개시 | Piper Sandler | Overweight |
| 2023-02-15 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-08-01 | 다운그레이드 | Truist | Buy → Hold |
| 2022-07-27 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-06-27 | 재개 | Canaccord Genuity | Buy |
| 2022-02-02 | 개시 | Canaccord Genuity | Buy |
| 2022-01-28 | 개시 | Truist | Buy |
| 2020-08-05 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-09-24 | 개시 | Jefferies | Buy |
| 2019-09-06 | 개시 | H.C. Wainwright | Buy |
| 2019-02-04 | 다운그레이드 | B. Riley FBR | Buy → Neutral |
| 2018-08-10 | 재확인 | Stifel | Hold |
| 2018-05-31 | 다운그레이드 | Stifel | Buy → Hold |
| 2018-03-09 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-08-31 | 개시 | Stifel | Buy |
| 2017-02-02 | 개시 | Ladenburg Thalmann | Buy |
| 2015-04-21 | 개시 | FBR Capital | Outperform |
| 2014-01-13 | 다운그레이드 | Stifel | Buy → Hold |
| 2013-08-09 | 다운그레이드 | Janney | Buy → Neutral |
| 2013-08-09 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2012-02-21 | 재확인 | JMP Securities | Mkt Outperform |
| 2010-01-06 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2008-07-17 | 개시 | Rodman & Renshaw | Mkt Outperform |
| 2007-06-21 | 업그레이드 | Punk, Ziegel & Co | Mkt Perform → Accumulate |
모두보기
코르셉트 테라퓨틱스 주식(CORT)의 최신 뉴스
CORT SEC FilingsCorcept Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Deadline Alert: Corcept Therapeutics Incorporated (CORT) - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Corcept Therapeutics Incorporated of Class Action Lawsuit and Upcoming DeadlinesCORT - PR Newswire
Zacks Research Has Pessimistic Outlook of CORT Q3 Earnings - MarketBeat
JPMorgan Chase & Co. Boosts Stock Position in Corcept Therapeutics Incorporated $CORT - MarketBeat
Corcept Therapeutics Shareholder Alert: ClaimsFiler Reminds - GlobeNewswire
Corcept Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Corcept Therapeutics Incorporated - GlobeNewswire Inc.
Robbins LLP Urges CORT Stockholders to Contact the Firm for Information About the Class Against Corcept Therapeutics Incorporated – Company AnnouncementFT.com - Financial Times
CORCEPT THERAPEUTICS INCORPORATED (CORT) - MSN
CORT Shareholder Notice: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Securities Class Action Following FDA Rejection and Federal Court Patent Loss - ChartMill
Shareholders of Corcept Therapeutics Incorporated Should Contact Levi & Korsinsky Before April 21, 2026 to Discuss Your RightsCORT - Finviz
Corcept Therapeutics Inc (NASDAQ:CORT): A GARP Pick with Accelerating Growth and a Solid Financial Base - ChartMill
Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - GlobeNewswire Inc.
CORT INVESTOR ALERT: Hagens Berman Alerts Corcept - GlobeNewswire
[Form 4] CORCEPT THERAPEUTICS INC Insider Trading Activity - Stock Titan
Corcept Therapeutics (CORT) director exercises 30K options and gifts shares - Stock Titan
ROSEN, A LEADING LAW FIRM, Encourages Corcept Therapeutics Incorporated to Secure Counsel ... - Bluefield Daily Telegraph
ROSEN, A LEADING LAW FIRM, Encourages Corcept Therapeutics Incorporated to Secure Counsel Before Important Deadline in Securities Class Action – CORT - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Corcept Therapeutics Incorporated of Class Action Lawsuit and Upcoming Deadlines – CORT - ChartMill
Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
Bronstein, Gewirtz & Grossman LLC Urges Corcept - GlobeNewswire
CORT Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Corcept Therapeutics Incorporated Securities Lawsuit -- The Gross Law Firm - PR Newswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
Corcept Therapeutics Incorporated Securities Fraud Class - GlobeNewswire
CORT ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Securities Class Action Following FDA Rejection and Federal Court Patent Loss - PR Newswire
Turning Pain Into Purpose - Women's Health
Portnoy Law Firm Announces Class Action on Behalf of Corcept Therapeutics Incorporated Investors - GlobeNewswire
Shareholders who lost money in shares of Corcept - GlobeNewswire
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law Firm – Company AnnouncementFT.com - Financial Times
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit - ChartMill
CORT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Shareholders of Corcept Therapeutics Incorporated to Contact the Firm Today! - ACCESS Newswire
Corcept Therapeutics (CORT) Is Down 5.1% After FDA Relacorilant Rejection And Investor LawsuitsWhat's Changed - simplywall.st
Checkpoint Capital L.P. Has $32.61 Million Stake in Corcept Therapeutics Incorporated $CORT - MarketBeat
A Look At Corcept Therapeutics (CORT) Valuation After Mixed Q4 And 2025 Results With Stronger 2026 Outlook - simplywall.st
CORT ALERT: Hagens Berman Alerts Corcept Therapeutics - GlobeNewswire
CORT Shareholder Alert: Corcept Therapeutics Incorporated - GlobeNewswire
Connor Clark & Lunn Investment Management Ltd. Purchases 51,864 Shares of Corcept Therapeutics Incorporated $CORT - MarketBeat
Capital Fund Management S.A. Has $13.33 Million Position in Corcept Therapeutics Incorporated $CORT - MarketBeat
CORT Stock Price, Quote & Chart | CORCEPT THERAPEUTICS INC (NASDAQ:CORT) - ChartMill
ROSEN, NATIONAL TRIAL COUNSEL, Encourages Corcept Therapeutics Incorporated to Secure Counsel Before Important Deadline in Securities Class ActionCORT - ACCESS Newswire
Corcept Therapeutics (CORT) Litigation: Hagens Berman Alerts Corcept (CORT) Investors to Securities Class Action and April 21 Lead Plaintiff Deadline - PR Newswire
Corcept Therapeutics Lawsuit: CORT Investors Face Losses After FDA Rejection and Alleged Misleading Statements - TipRanks
CORCEPT THERAPEUTICS INCORPORATED (CORT) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds ... - Bluefield Daily Telegraph
CORCEPT THERAPEUTICS INCORPORATED (CORT) SHAREHOLDER ALERT - GlobeNewswire
CORT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Corcept Therapeutics Incorporated Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
Lawsuit filed for Investors who lost money with shares of Corcept Therapeutics Incorporated (NASDAQ: CORT) - openPR.com
ROSEN, A LEADING NATIONAL FIRM, Encourages Corcept Therapeutics Incorporated to Secure Counsel ... - Bluefield Daily Telegraph
H.C. Wainwright Cuts Corcept Therapeutics Incorporated (CORT) Price Target, Keeps Buy Rating - Yahoo Finance
Corcept Therapeutics Shareholders Are Encouraged to Contact Johnson Fistel for More Information About Potentially Recovering Their Losses - marketscreener.com
Corcept Therapeutics Shareholders Are Encouraged to Contact - GlobeNewswire
코르셉트 테라퓨틱스 (CORT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):